Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity

References

• SheebaCJMarslinGRevinaAMFranklinGSignaling pathways influencing tumor microenvironment and their exploitation for targeted drug deliveryNanotechnol Rev201432123151
   Web of Science ®Google Scholar
• DrukerBJTamuraSBuchdungerEEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cellsNat Med1996255615668616716
   PubMed Web of Science ®Google Scholar
• CarrollMOhno-JonesSTamuraSCGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteinsBlood19979012494749529389713
   PubMed Web of Science ®Google Scholar
• HeinrichMCGriffithDJDrukerBJWaitCLOttKAZiglerAJInhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitorBlood200096392593210910906
   PubMed Web of Science ®Google Scholar
• DanhierFAnsorenaESilvaJMCocoRLe BretonAPréatVPLGA-based nanoparticles: an overview of biomedical applicationsJ Control Release2012161250552222353619
   PubMed Web of Science ®Google Scholar
• EliasMHBabaAAAzlanHBCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcomeLeuk Res201438445445924456693
   PubMed Web of Science ®Google Scholar
• DinOSWollPJTreatment of gastrointestinal stromal tumor: focus on imatinib mesylateTher Clin Risk Manag20084114916218728705
   PubMedGoogle Scholar
• AndraeJGalliniRBetsholtzCRole of platelet-derived growth factors in physiology and medicineGenes Dev200822101276131218483217
   PubMed Web of Science ®Google Scholar
• LennartssonJRönnstrandLStem cell factor receptor/c-Kit: from basic science to clinical implicationsPhysiol Rev20129241619164923073628
   PubMed Web of Science ®Google Scholar
• RainesEWPDGF and cardiovascular diseaseCytokine Growth Factor Rev200415423725415207815
   PubMed Web of Science ®Google Scholar
• ForceTKrauseDSVan EttenRAMolecular mechanisms of cardiotoxicity of tyrosine kinase inhibitionNat Rev Cancer20077533234417457301
   PubMed Web of Science ®Google Scholar
• HermanEHKnaptonARosenEA multifaceted evaluation of imatinib-induced cardiotoxicity in the ratToxicol Pathol20113971091110621937741
   PubMed Web of Science ®Google Scholar
• KerkeläRGrazetteLYacobiRCardiotoxicity of the cancer therapeutic agent imatinib mesylateNat Med200612890891616862153
   PubMed Web of Science ®Google Scholar
• MaharsyWAriesAMansourOKomatiHNemerMAgeing is a risk factor in imatinib mesylate cardiotoxicityEur J Heart Fail201416436737624504921
   PubMed Web of Science ®Google Scholar
• ChenYYangWChangBHuHFangXShaXIn vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluationEur J Pharm Biopharm2013853 Pt A40641223816639
   PubMed Web of Science ®Google Scholar
• MaksimenkoAMouginJMuraSPolyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapyCancer Lett2013334234635322935679
   PubMed Web of Science ®Google Scholar
• MaoJNLiAJZhaoLPPEG-PLGA nanoparticles entrapping doxorubicin reduced doxorubicin-induced cardiotoxicity in ratsAdv Mat Res2014912263268
   Google Scholar
• MarslinGSheebaCJKalaichelvanVKManavalanRReddyPNFranklinGPoly(D,L-lactic-co-glycolic acid) nanoencapsulation reduces Erlotinib-induced subacute toxicity in ratJ Biomed Nanotechnol20095546447120201419
   PubMed Web of Science ®Google Scholar
• NasrMNafeeNSaadHKazemAImproved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in miceEur J Pharm Biopharm201488121622524813390
   PubMed Web of Science ®Google Scholar
• YuanAWuJSongCA novel self-assembly albumin nanocarrier for reducing doxorubicin-mediated cardiotoxicityJ Pharm Sci201310251626163523423631
   PubMed Web of Science ®Google Scholar
• KimuraSEgashiraKNakanoKLocal delivery of imatinib mesylate (STI571)-incorporated nanoparticle ex vivo suppresses vein graft neointima formationCirculation200811814 SupplS65S7018824771
   PubMed Web of Science ®Google Scholar
• MendoncaLSMoreiraJNde LimaMCSimõesSCo-encapsulation of anti-BCR-ABL siRNA and imatinib mesylate in transferrin receptor-targeted sterically stabilized liposomes for chronic myeloid leukemia treatmentBiotechnol Bioeng2010107588489320632368
   PubMed Web of Science ®Google Scholar
• ThampiRGGodwinSEHarishGDesign and characterization of nanoparticulate drug delivery system of an anticancer drug: Imatinib mesylateIndian J Res Pharm Biotech201410821087
   Google Scholar
• PalamàIELeporattiSde LucaEImatinib-loaded polyelectrolyte microcapsules for sustained targeting of BCR-ABL+ leukemia stem cellsNanomedicine (Lond)20105341943120394535
   PubMed Web of Science ®Google Scholar
• Karal-YilmazOOzkanAAkgunEControlled release of imatinib mesylate from PLGA microspheres inhibit craniopharyngioma mediated angiogenesisJ Mater Sci Mater Med201324114715323053813
   PubMed Web of Science ®Google Scholar
• BennyOMenonLGArielGLocal delivery of poly lactic-co-glycolic acid microspheres containing imatinib mesylate inhibits intracranial xenograft glioma growthClin Cancer Res20091541222123119190128
   PubMed Web of Science ®Google Scholar
• SikharamSRelease Kinetics of Imatinib Mesylate from a Thermosensitive Polymer and its Effect on Vascular Smooth Muscle Cells [dissertation]Salt Lake CityThe University of Utah2011
   Google Scholar
• FanYDuWHeBThe reduction of tumor interstitial fluid pressure by liposomal imatinib and its effect on combination therapy with liposomal doxorubicinBiomaterials20133492277228823290525
   PubMed Web of Science ®Google Scholar
• ZhangXDWuDShenXSize-dependent in vivo toxicity of PEG-coated gold nanoparticlesInt J Nanomedicine201162071208121976982
   PubMed Web of Science ®Google Scholar
• KaleemuddinMSrinivasPLyophilized oral sustained release polymeric nanoparticles of nateglinideAAPS Pharm Sci Tech20131417885
   PubMed Web of Science ®Google Scholar
• KarmenAWroblewskiFLa DueJSTransaminase activity in human bloodJ Clin Invest195534112613113221663
   PubMed Web of Science ®Google Scholar
• KalariaDRSharmaGBeniwalVRavi KumarMNDesign of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in ratsPharm Res200926349250118998202
   PubMed Web of Science ®Google Scholar
• LeeSJWangJYExploiting the promiscuity of imatinibJ Biol2009833019435483
   PubMedGoogle Scholar
• SaadSYAlkharfyKMArafahMMCardiotoxic effects of arsenic trioxide/imatinib mesilate combination in ratsJ Pharm Pharmacol200658456757316597375
   PubMed Web of Science ®Google Scholar
• JainAKSwarnakarNKDasMAugmented anticancer efficacy of doxorubicin-loaded polymeric nanoparticles after oral administration in a breast cancer induced animal modelMol Pharm2011841140115121557558
   PubMed Web of Science ®Google Scholar